Ангиотензины и ревматоидный артрит

В настоящее время хорошо изучена роль ренин-ангиотензиновой системы (РАС) в регуляции деятельности сердечно-сосудистой системы и поддержании водно-электролитного гомеостаза. Однако за последние десятилетия были идентифицированы новые компоненты РАС, позволяющие предполагать более широкий спектр ее потенциального воздействия на организм. Принципиально важной для ревматологов является возможность воздействовать на воспаление, в том числе и ревматоидное, посредством блокады образования ангиотензина (АТ) II с помощью эффектов АТ 1–7 и ингибиторов ангиотензинпревращающего фермента, а также подавления процессов ангиогенеза, в первую очередь, за счет снижения выработки эндотелиального фактора роста. Органопротективный и противовоспалительный потенциал лекарственных препаратов, уменьшающих выработку АТ, доказанный в экспериментах in vitro и in vivo, позволяет рассматривать их как ангиотропные средства первого ряда у пациентов с ревматоидным артритом, особенно при наличии сопутствующей артериальной гипертензии и/или нефропатии.

ренин-ангиотензиновая система, ангиотензины, ингибиторы ангиотензинпревращающего фермента, блокаторы ангиотензиновых рецепторов, воспаление, ревматоидный артрит

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8

2. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-37. doi: 10.1016/S0140-6736(17)31472-1

3. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with RA: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690-7. doi: 10.1002/art.24092

4. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. doi: 10.1016/j.acvd.2010.03.007

5. Вайсман ДШ, Сороцкая ВН, Никитина ЕС. Анализ смертности от болезней костно-мышечной системы по первоначальной и множественным причинам у жителей Тульской области. Научно-практическая ревматология. 2017;55(6):616-20 [Vaysman DSh, Sorotskaya VN, Nikitina ES. Analysis of mortality from musculoskeletal diseases as underlying and multiple causes in the residents of the Tula Region. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):616-20 (In Russ.)]. doi: 10.14412/1995-4484-2017-616-20

6. Шутов АМ, Серов ВА. Кардиоренальный континуум или кардиоренальный синдром? Клиническая нефрология. 2010;2(1):44-8 [Shutov AM, Serov VA. Cardiorenal continuum or cardiorenal syndrome? Klinicheskaya Nefrologiya. 2010;2(1):44-8 (In Russ.)].

7. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for opharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439-65. doi: 10.1146/annurev.pharmtox.010909.105610

8. Lautner RQ, Villela DC, Fraga-Silva RA, et al. Discovery and characterization of alamandine: a novel component of the reninangiotensin system. Circ Res. 2013 Apr 12;112(8):1104-11. doi: 10.1161/CIRCRESAHA.113.301077

9. Villela DC, Passos-Silva DG, Santos RA. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens. 2014 Mar; 23(2):130-4. doi: 10.1097/01.mnh.0000441052.44406.92

10. Etelvino GM, Peluso AA, Santos RA. New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D. Curr Hypertens Rep. 2014 Jun;16(6):433. doi: 10.1007/s11906-014-0433-0

11. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121:S21-31. doi: 10.1016/j.amjmed.2008.06.014

12. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population based cohort study. Arthritis Rheum 2008;58:2268-74. doi: 10.1002/art.23650

13. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. This article is protected by copyright. All rights reserved. Gastroenterology. 2000;118:1149-56. doi: 10.1016/S0016-5085(00)70368-4

14. Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest. 1999;104:1693-701. doi: 10.1172/JCI7451

15. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367-74. doi: 10.1016/j.tips.2008.05.003

16. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy. 2005;25:1213-29. doi: 10.1592/phco.2005.25.9.1213

17. Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter of love and hate. Peptides. 2005;26:1401-9. doi: 10.1016/j.peptides.2005.03.010

18. De Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology: XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-72.

19. Widdop R, Jones E, Hannan R, Gaspari T. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-24. doi: 10.1038/sj.bjp.0705448

20. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 1995;25:913-7. doi: 10.1161/01.HYP.25.5.913

21. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y, et al. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood. 2004;104:402-8. doi: 10.1182/blood-2003-08-2974

22. Piqueras L, Kubes P, Alvarez A, et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 2000;102:2118-23. doi: 10.1161/01.CIR.102.17.2118

23. Nobuhiko A, Suganuma E, Babaev VR, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2143-8. doi: 10.1161/01.ATV.0000145607.03879.e0

24. Han C, Liu J, Liu X, Li M. Angiotension II induces C-reactive protein expression Accepted through ERK1/2 and JNK signaling in human aortic cells. Atherosclerosis. 2010;212:206-12. doi: 10.1016/j.atherosclerosis.2010.05.020

25. Silveira KD, Coelho FM, Vieira AT, et al. Mechanisms of the antiinflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Peptides. 2013 Aug;46:53-63. doi: 10.1016/j.peptides.2013.05.012

26. Refaat R, Salama M, Abdel Meguid E, et al. Evaluation of the effect of losartan and methotrexate combined therapy in adjuvantinduced arthritis in rats. Eur J Pharmacol. 2013 Jan 5;698(1-3):421-8. doi: 10.1016/j.ejphar.2012.10.024

27. Wang D, Hu S, Zhu J, et al. Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvantinduced arthritis. J Cell Mol Med. 2013 Dec;17(12):1577-87. doi: 10.1111/jcmm.12128

28. Agha AM, Mansour M. Effects of captopril on interleukin-6, leukotriene B(4), and oxidative stress markers in serum and inflammatory exudate of arthritic rats: vidence of anti-inflammatory activity. Toxicol Appl Pharmacol. 2000 Oct 15;168(2):123-30. doi: 10.1006/taap.2000.8985

29. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung. 1986 Nov;36(11):1605-8.

30. Dalbeth N, Edwards J, Fairchild S, et al. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford). 2005 Jan;44(1):24- 31. doi: 10.1093/rheumatology/keh398

31. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum. 2005 Jun;52(6):1920-8. doi: 10.1002/art.21040

32. Sakuta T, Morita Y, Satoh M, et al. Involvement of the reninangiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum. 2010 May;62(5):1319-28. doi: 10.1002/art.27384

33. Марченко ЖС, Лукина ГВ. Роль сосудистого эндотелиального фактора роста в патогенезе ревматоидного артрита. Научно-практическая ревматология. 2005;43(1):57- 60 [Marchenko ZhS, Lukina GV. Role of vascular endothelial growth factor in pathogenesis of rheumatoid arthritis. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2005;43(1):57-60 (In Russ.)]. doi: 10.14412/1995-4484-2005-558

34. Clavel G, Boissier MC. Angiogenesis Markers in Rheumatoid Arthritis. Future Rheumatol. 2008;3(2):153-9. doi: 10.2217/17460816.3.2.153

35. Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol. 2009 Jun;90(3):249-61. doi: 10.1111/j.1365-2613.2009.00640.x

36. Vreju F, Ciurea M, Rosu A, et al. Power Doppler sonography, a non-invasive method of assessment of the synovial inflammation in patients with early rheumatoid arthritis. Rom J Morphol Embryol. 2011;52(2):637-43.

37. Schroeder M, Viezens L, Fuhrhop I, et al. Angiogenic growth factors in rheumatoid arthritis. Rheumatol Int. 2013 Feb;33(2):523-7. doi: 10.1007/s00296-011-2210-6

38. Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta. 2007 Jan;375(1-2):10-9. doi: 10.1016/j.cca.2006.06.033

39. Rueda B, Gonzalez-Gay MA, Lopez-Nevot MA, et al. Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis. Hum Immunol. 2005 Aug;66(8):864-8. doi: 10.1016/j.humimm.2005.05.004

40. Новиков АА, Александрова ЕН, Диатроптова MA, Насонов ЕЛ. Роль цитокинов в патогенезе ревматоидного артрита. Научно-практическая ревматология. 2010;48(2):71-82 [Novikov AA, Aleksandrova EN, Diatroptova MA, Nasonov EL. Role of cytokines in the pathogenesis of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(2):71-82 (In Russ.)]. doi: 10.14412/1995-4484-2010-1420

41. Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm. 2008;2008:129873. doi: 10.1155/2008/129873

42. Napoleone E, Cutrone A, Cugino D, et al. Inhibition of the reninangiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells. Thromb Res. 2012 Jun;129(6):736-42. doi: 10.1016/j.thromres.2011.11.047

43. Kim S, Toyokawa H, Yamao J, et al. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Pancreas. 2014 Aug;43(6):886-90. doi: 10.1097/MPA.0000000000000125

44. Park YA, Choi CH, Do IG, et al. Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecol Oncol. 2014 Oct;135(1):108-17. doi: 10.1016/j.ygyno.2014.06.031

45. Walsh DA, Suzuki T, Knock GA, et al. AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol. 1994 Jun;112(2):435-42. doi: 10.1111/j.1476-5381.1994.tb13091.x

46. Price A, Lockhart JC, Ferrell WR, et al. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Arthritis Rheum. 2007 Feb;56(2):441-7. doi: 10.1002/art.22335

47. Kawakami Y, Matsuo K, Murata M, et al. Expression of angiotensin II receptor-1 in human articular chondrocytes. Arthritis. 2012;2012:648537. doi: 10.1155/2012/648537

48. Goto M, Fujisawa M, Yamada A, et al. Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis. 1990 Mar;49(3):172-6. doi: 10.1136/ard.49.3.172

49. Goto M, Sasano M, Fuzisawa M, et al. Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions. Ann Rheum Dis. 1992 Jun;51(6):741-2. doi: 10.1136/ard.51.6.741

50. Veale D, Yanni G, Bresnihan B, FitzGerald O. Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann Rheum Dis. 1992 Apr;51(4):476-80. doi: 10.1136/ard.51.4.476

51. Walsh DA, Catravas J, Wharton J. Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. Ann Rheum Dis. 2000 Feb;59(2):125-31. doi: 10.1136/ard.59.2.125

52. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factoralpha in vitro and in vivo. Immunopharmacology. 1997 Apr;36(1):49-55. doi: 10.1016/S0162-3109(96)00160-9

53. Martin MF, Surrall KE, McKenna F, et al. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325-8. doi: 10.1016/S0140-6736(84)91821-X

54. Bird HA, Le Gallez P, Dixon JS, et al. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol. 1990 May;17(5):603-8.

55. Flammer AJ, Sudano I, Hermann F, et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008 Apr 29;117(17):2262-9. doi: 10.1161/CIRCULATIONAHA.107.734384

56. Perry ME, Chee MM, Ferrell WR, et al. Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Nov;67(11):1646- 7. doi: 10.1136/ard.2007.082917

57. Da Silveira KD, Coelho FM, Vieira AT, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010 Nov 1;185(9):5569-76. doi: 10.4049/jimmunol.1000314

58. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-11. doi: 10.1016/S0140-6736(01)06075-5

59. Boers M. Renal disorders in rheumatoid arthritis. Semin Arthritis Rheum. 1990;20:57-68. doi: 10.1016/0049-0172(90)90095-W

60. Ramirez G, Lambert R, Bloomer HA. Renal pathology in patients with rheumatoid arthritis. Nephron. 1981;28:124-6. doi: 10.1159/000182132

61. Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154-60.

62. Yoshida A, Morozumi K, Suganuma T, et al. Clinicopathological study of nephropathy in patients with rheumatoid arthritis. Ryumachi. 1991;31:14-21.

63. Pathan E, Joshi VR. Rheumatoid arthritis and the kidney. J Assoc Physicians Ind. 2004;52:488-94.

64. Laakso M, Mutru O, Isomä ki H, Koota K. Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis. Ann Rheum Dis. 1986;45:663-7. doi: 10.1136/ard.45.8.663

65. Santos SH, Andrade JM, Fernandes LR, et al. Oral angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NFkB in rats fed with high-fat diet. Peptides. 2013 Aug;46:47-52. doi: 10.1016/j.peptides.2013.05.010

66. Mori J, Patel VB, Ramprasath T, et al. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation and lipotoxicity. Am J Physiol Renal Physiol. 2014 Apr 15;306(8):812-21. doi: 10.1152/ajprenal.00655.2013

67. Benicky J, Sanchez-Lemus E, Honda M, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011 Mar;36(4):857-70. doi: 10.1038/npp.2010.225

68. Saavedra JM. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond). 2012 Nov;123(10):567-90. doi: 10.1042/CS20120078

69. Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens. 2015 Mar;28(3):289-99. doi: 10.1093/ajh/hpu197

70. El-Hashim AZ, Renno WM, Raghupathy R, et al. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kB-dependent pathways. Br J Pharmacol. 2012 Jul;166(6):1964-76. doi: 10.1111/j.1476-5381.2012.01905.x

71. Costa AC, Romero TR, Pacheco DF, et al. Participation of AT1 and Mas receptors in the modulation of inflammatory pain. Peptides. 2014 Nov;61:17-22. doi: 10.1016/j.peptides.2014.08.010

72. Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637-47. doi: 10.1016/S0140-6736(13)62337-5

73. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007 Oct;13(8 Suppl B):9-20. doi: 10.18553/jmcp.2007.13.s8-b.9

74. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev. 2006 Jul;86(3):747-803. doi: 10.1152/physrev.00036.2005

75. Ruiz-Ortega M, Esteban V, RupОrez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006 Mar;15(2):159-66. doi: 10.1097/01.mnh.0000203190.34643.d4

76. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005 Dec 10;366(9502):2026-33. doi: 10.1016/S0140-6736(05)67814-2

77. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006 Jul;48(1):8-20. doi: 10.1053/j.ajkd.2006.04.077

78. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab. 1998;24(2-3):174-80. doi: 10.1159/000057367

79. Yoo KH, Thornhill BA, Wolstenholme JT, Chevalier RL. Tissuespecific regulation of growth factors and clusterin by angiotensin II. Am J Hypertens. 1998 Jun;11(6 Pt 1):715-22. doi: 10.1016/S0895-7061(98)00018-1

80. Wolak T, Kim H, Ren Y, et al. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int. 2009 Jul;76(1):32-43. doi: 10.1038/ki.2009.90

81. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006 Dec;70(11):1914-9. doi: 10.1038/sj.ki.5001846

82. Gounder VK, Arumugam S, Arozal W, et al. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats. Int Immunopharmacol. 2014 Feb;18(2):282-9. doi: 10.1016/j.intimp.2013.11.018

83. Batlle D, Wysocki J, Soler MJ, Ranganath K. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int. 2012 Mar;81(6):520-8. doi: 10.1038/ki.2011.381

84. Wong DW, Oudit GY, Reich H, et al. Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. Am J Pathol. 2007 Aug;171(2):438-51. doi: 10.2353/ajpath.2007.060977

85. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2010 Mar;298(3):F579-88. doi: 10.1152/ajprenal.00548.2009

86. Montecucco F, Mach F. Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab. 2009 Jun;23(3):389-400. doi: 10.1016/j.beem.2008.12.003

87. Protogerou AD, Panagiotakos DB, Zampeli E, et al. Arterial hypertension assessed 'out-of-office' in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated 'white coat' phenomenon. Arthritis Res Ther. 2013 Oct 2;15(5):R142. doi: 10.1186/ar4324